Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models

Kawasaki, N; Tomita, M; Yamashita-Kashima, Y; Yoshimura, Y; Yoshiura, S

Yoshiura, S (通讯作者)，Chugai Pharmaceut Co Ltd, Prod Res Dept, 216 Totsuka Cho, Totsuka Ku, Yokohama, Kanagawa 2448602, Japan.

LEUKEMIA & LYMPHOMA, 2023; 64 (12): 1938

Abstract

Polatuzumab vedotin (Pola) was approved for first-line and relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in many countries. This mea......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索